Page 77 - Helicobacter pylori and Gastric Cancer: From Tumor microenvironment to Immunotherapy

45. Howard, S.H., et al., Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)- high metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 2017. 35(4_suppl): p. 673-673.
46. David, F.M., et al., Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. Journal of Clinical Oncology, 2016. 34(8): p. 833-842.
47. Spahn J Fau - Spahn, J., et al., Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models. (2051-1426 (Electronic)).
48. Kelly Rj Fau - Kelly, R.J., et al., Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma. (2051-1426 (Electronic)).
49. Wolchok, J.D., et al., Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci, 2013. 1291(1): p. 1-13.
50. Antonia, S.J., et al., Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open- label, phase 1/2 trial. Lancet Oncol, 2016. 17(7): p. 883-895.
51. Wolchok, J.D., et al., Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2013. 369(2): p. 122-133.
52. Josep, T., et al., KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology, 2016. 34(4_suppl): p. TPS185-TPS185.
53. Atsushi, O., et al., Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study. Journal of Clinical Oncology, 2016. 34(15_suppl): p. TPS4137-TPS4137.
Immunotherapy Checkpoint Inhibition
Immuno checkpoint inhibition
71
75
3